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variables. RESULTS: Of the 2624 home-testing participants, the
overall HbA1c test completion rate was 49.5%, with males sig-
niﬁcantly more likely to complete the test than females (52.3%
vs. 46.1%; c2: p = 0.001). Although home-testing participation
increased signiﬁcantly with age (c2: p < 0.0001), a signiﬁcantly
lower rate of participation was observed at the highest level of
disease severity (c2: p = 0.0006). No signiﬁcant relationship
between participation and income level existed. There was a sig-
niﬁcant interaction effect between age and gender, with the rela-
tionship between gender and home-testing participation
reversing as age increased (CMH: p < 0.0001). Gender also sig-
niﬁcantly mediated the impact of disease severity on participa-
tion (CMH: p = 0.001), with the impact of increased disease
severity occurring only for females (c2: p < 0.0001). CONCLU-
SIONS: This study suggests that signiﬁcant differences in
program responsiveness exist by demographic and condition-
speciﬁc variables. Strategies to effectively target these segments
of lower responsiveness will improve the viability and success of
a home-based A1c monitoring program.
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OBJECTIVE: The value of self-monitoring of blood glucose
(SMBG) by patients with type 2 diabetes is controversial. The
objective of this study is to examine the relationship between
SMBG and glycemic control among veterans who receive oral
hypoglycemic medications only for diabetes. METHODS:
Veterans with diabetes mellitus at a Texas Veterans Health care
System were selected by identifying those with an ICD-9 code
for diabetes from the outpatient ﬁle. Veterans who received con-
tinuous care at the VA from FY 2000 to 2002 were selected.
From this cohort, a sub cohort of veterans was identiﬁed who
received oral hypoglycemic medications only during all 3 years
of study period. The cohort was placed into 4 mutually exclu-
sive groups based on the duration of SMBG. These groups were
deﬁned as “did not receive monitoring strips at all”; “received
last year”; “received last 2 years”; and “received all 3 years”.
RESULTS: Of the 1185 veterans who received oral hypoglycemic
medications, 976 veterans met the criteria for one of the groups.
There were no signiﬁcant differences among the groups on base-
line Hba1c, BMI, casemix score. There were signiﬁcant differ-
ences in age and race. Pairwise comparison showed that mean
rank for age was older among those who did not receive strips
at all compared to those who received strips the last year (p <
0.0083). Results of robust regression showed that age and being
Hispanic (compared to white) were signiﬁcant predictors of
Hba1c at FY 2002 (controlling for baseline Hba1c). (F = 49.77
(9, 906 p < 0.001). Age was inversely related to Hba1c. Dura-
tion of monitoring (including not monitoring at all) was not a
signiﬁcant predictor of Hba1c at FY 2002. CONCLUSIONS:
The results suggest there were some signiﬁcant differences in age
and race among those who received monitoring supplies and
those who did not. Receiving strips and duration of receiving
strips were not signiﬁcantly associated with glycemic control.
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OBJECTIVES: Previous research has found that women with
diabetes are at a higher risk for cardiovascular disease mortality
than men with diabetes. The purpose of this study was to deter-
mine whether there were gender-related differences in the man-
agement of dyslipidemia in managed care enrollees with diabetes.
METHODS: Retrospective cross-sectional analyses were con-
ducted using medical and pharmacy claims data from a large
health maintenance organization across a two-year period
(2000-1). Patients with type-2 diabetes were identiﬁed through
a validated algorithm of medication and diagnosis codes. Bivari-
ate analyses were conducted with chi-square analysis to deter-
mine if women were less likely than men to receive a lipid test
or a lipid-modifying drug. Logistic regression models were also
constructed to compare gender-related differences while con-
trolling for age and illness severity. Prior hospitalization and the
intensity of diabetes drug therapy served as proxies for illness
severity. All statistical analyses were performed using SPSS,
version 11.0. RESULTS: A total of 2360 patients with type-2
diabetes were included in the analyses. Across 2000 and 2001,
79.4% of women received a lipid test as compared to 84.2% of
men (chi-square = 6.69, p = 0.01). Also, 33.2% of women
received a lipid-modifying drug as compared to 45.5% of men
(chi-square = 27.31, p < 0.001). Logistic regression analyses
revealed that men were more likely than women to receive a lipid
test when controlling for age, hospitalization in year 2000, and
intensity of diabetes drug therapy (OR = 1.42, CI = 1.09 to 1.84).
Men were also more likely than women to receive a lipid-
modifying drug when controlling for age, prior hospitalization,
diabetes drug intensity and lipid-testing (OR = 1.57, CI = 1.28
to 1.94). CONCLUSIONS: Women with type-2 diabetes were
less likely than men with type-2 diabetes to receive lipid tests or
lipid-modifying drugs.
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OBJECTIVES: To compare the risk of diabetes associated with
olanzapine, quetiapine, and risperidone in treating patients with
schizophrenia. METHODS: Schizophrenia patients taking
mono-atypical therapy were selected from North Carolina Med-
icaid Claims database from July 1998 through October 2000.
Patients were included if they were continuously eligible in the
North Carolina Medicaid program with no diagnosis of diabetes
during the three-month pre-treatment period. While controlling
for patient demographic and clinical characteristics, comorbidi-
ties, and medication use in the baseline period, multivariate logit
models were employed to compare the odds ratios for diabetes
associated with atypical antipsychotic treatments. RESULTS:
A total of 581 patients were included. Of these, 322 initiated
olanzapine, 44 initiated quetiapine, and 215 initiated risperi-
done. Mean age was 40.7 years, 54.7% were men and 46% were
whites. No statistically signiﬁcant differences were found in rates
of diabetes among the three cohorts, where the adjusted odds
ratio and 95% conﬁdence intervals were 1.39 (0.684–2.838) for
olanzapine vs. risperidone, 0.897 (0.255–3.155) for olanzapine
vs. quetiapine, and 0.973 (0.495–1.914) for quetiapine vs.
risperidone. Otherwise, all included factors being equal, a higher
risk of diabetes appeared to be associated with female and the
prior use of antidepressants. CONCLUSIONS: Based on the NC
Medicaid population, the risk of diabetes for patients with schiz-
ophrenia did not appear to differ across the treatment groups of
olanzapine, quetiapine, and risperidone.
